Skip to main content

Table 3 Linear regression analysis with log-transformed serum CGRP-LI levels (mol/l) T1

From: Serum CGRP in migraine patients using erenumab as preventive treatment

Variable β (95% CI)1 p β (95% CI)2 p
Age 0.07 (-0.001–0.13) 0.05 0.044 (-0.03 − 0.12) 0.24
Sex 1.92 (-0.41–4.25) 0.10 2.979 (0.65–5.31) 0.01
Migraine days baseline 0.09 (-0.06–0.24) 0.24 0.10 (-0.06–0.25) 0.22
Serum CGRP-LI -2.12 (-3.44 - -0.80) 0.002 -2.13 (-3.52 - -0.73) 0.003
 N = 89. 1Simple linear regression. 2multiple regression, corrected for all tested variables. CI = confidence interval. T1 = 2–4 weeks after starting treatment with erenumab. The outcome is absolute reduction migraine days during month 3 after starting treatment with erenumab compared to baseline. One month is defined as 28 days.